AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35777732 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive incentive ($0.10/test)
Number of subjects: 130
Study 35777732 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss aversion ($100 for > 95% adherence)
Number of subjects: 130
Study 35777732 — intervention group
Group type: COMPARATOR
Intervention: Control ($25 upon enrollment)
Number of subjects: 130
Study 32237012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose spironolactone (100 mg daily)
Number of subjects: 149
Study 32237012 — intervention group
Group type: COMPARATOR
Intervention: Low-dose spironolactone (25 mg daily)
Number of subjects: 149
Study 37083373 — intervention group
Group type: EXPERIMENTAL
Intervention: sabatolimab + azacitidine
Number of subjects: 0
Study 33497396 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking (UCM)
Number of subjects: 260
Study 33497396 — intervention group
Group type: COMPARATOR
Intervention: Delayed Cord Clamping (DCC)
Number of subjects: 260
Study 32531809 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour illusion (blue tongue)
Number of subjects: 9
Study 32531809 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition (normal size and colour tongue)
Number of subjects: 9
Study 35637354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck stretching and movement exercises three times daily for four weeks post-surgery
Number of subjects: 89
Study 35637354 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up without exercises
Number of subjects: 89
Study 34064102 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative Roots® (INT)
Number of subjects: 46
Study 34064102 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 46
Study 33029792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid for PPH
Number of subjects: 18942
Study 33952629 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 0
Study 32699404 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte telomere length (LTL)
Number of subjects: 81000
Study 34468959 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 40
Study 34468959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33279389 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 0
Study 33279389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dabigatran (150 mg bid), rivaroxaban, high-dose edoxaban (60 mg daily)
Number of subjects: 0
Study 33279389 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment with aspirin and P2Y12 receptor antagonists
Number of subjects: 0
Study 33279389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 33279389 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs (Direct Oral Anticoagulants)
Number of subjects: 0
Study 33279389 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori treatment
Number of subjects: 0
Study 35137572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium prolonged release (Li-PR)
Number of subjects: 73
Study 35137572 — intervention group
Group type: COMPARATOR
Intervention: Lithium immediate release (Li-IR)
Number of subjects: 73
Study 35137572 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction questionnaire
Number of subjects: 73
Study 34308096 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 636
Study 34308096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study 35112931 — intervention group
Group type: EXPERIMENTAL
Intervention: BH4 (≈10 mg/kg, post)
Number of subjects: 22
Study 35112931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both approaches
Number of subjects: 22
Study 35112931 — intervention group
Group type: EXPERIMENTAL
Intervention: BH4 supplementation
Number of subjects: 22
Study 34746173 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based support program (SUPR)
Number of subjects: 138
Study 34746173 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPR
Number of subjects: 138
Study 35775183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 19
Study 35775183 — intervention group
Group type: COMPARATOR
Intervention: Hybrid fixation
Number of subjects: 19
Study 34065588 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing images of nature
Number of subjects: 30
Study 34065588 — intervention group
Group type: COMPARATOR
Intervention: Viewing images of built environments
Number of subjects: 30
Study 32050789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subcostal transversus abdominis plane (TAP) block with 30 mL local anesthetic (20 mL bupivacaine 0.125% plus 10 mL lidocaine 1%)
Number of subjects: 79
Study 32050789 — intervention group
Group type: COMPARATOR
Intervention: IV analgesic management with paracetamol 1 g
Number of subjects: 79
Study 34724584 — intervention group
Group type: EXPERIMENTAL
Intervention: THUNDERBEAT
Number of subjects: 60
Study 34724584 — intervention group
Group type: COMPARATOR
Intervention: LigaSure
Number of subjects: 60
Study 33207014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU/d for 9 months)
Number of subjects: 250
Study 33207014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 33207014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 250
Study 35190895 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, Early Comprehensive Rehabilitation Program (t-ECRP)
Number of subjects: 215
Study 35190895 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 215
Study 34903242 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANNs)
Number of subjects: 3699
Study 34903242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Linear Regression (MLR)
Number of subjects: 3699
Study 34903242 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification and Regression Tree (CART)
Number of subjects: 3699
Study 34154951 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention (two additional 1-hour sessions focused on the benign nature of LBP)
Number of subjects: 202
Study 34154951 — intervention group
Group type: COMPARATOR
Intervention: Sham patient education (active listening only)
Number of subjects: 202
Study 34154951 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling reassured (mediator)
Number of subjects: 202
Study 33579199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group (8 mg dexamethasone with 0.375% ropivacaine)
Number of subjects: 132
Study 33579199 — intervention group
Group type: COMPARATOR
Intervention: Control group (ropivacaine only)
Number of subjects: 132
Study 33579199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 132
Study 33579199 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 32424409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient feedback intervention
Number of subjects: 43
Study 35976631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 35976631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33972313 — intervention group
Group type: EXPERIMENTAL
Intervention: Early screening for undiagnosed diabetes and early hyperglycemia in pregnancy
Number of subjects: 0
Study 33972313 — intervention group
Group type: COMPARATOR
Intervention: Current management regimen for GDM diagnosed at 24-28 weeks' gestation
Number of subjects: 0
Study 33998024 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy visits (SPT) with regularity
Number of subjects: 0
Study 33998024 — intervention group
Group type: COMPARATOR
Intervention: Supportive periodontal therapy visits (SPT) with irregularity
Number of subjects: 0
Study 33998024 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive periodontal therapy visits (SPT)
Number of subjects: 0
Study 33069413 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum (COL)
Number of subjects: 27
Study 33069413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 colostrum:whole milk mixture (MX)
Number of subjects: 27
Study 33069413 — intervention group
Group type: COMPARATOR
Intervention: Whole milk (WM)
Number of subjects: 27
Study 36017704 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 543
Study 36017704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study 33411640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h passive heating (40°C water) 30 min before an OGTT (HOT-OGTT)
Number of subjects: 12
Study 33411640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h passive heating (40°C water) 30 min after commencing an OGTT (OGTT-HOT)
Number of subjects: 12
Study 33411640 — intervention group
Group type: COMPARATOR
Intervention: 3-h OGTT (control)
Number of subjects: 12
Study 35040869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (vitE), dosage not specified, duration 3 years (baseline to year 3)
Number of subjects: 1144
Study 35040869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (vitE) in never smokers
Number of subjects: 1144
Study 35040869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (vitE) in current smokers
Number of subjects: 1144
Study 35040869 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (vitE) in former smokers
Number of subjects: 1144
Study 33333334 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban)
Number of subjects: 41
Study 33333334 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily regimen of direct oral anticoagulants
Number of subjects: 41
Study 33712967 — intervention group
Group type: EXPERIMENTAL
Intervention: Swab protocol
Number of subjects: 25
Study 33712967 — intervention group
Group type: COMPARATOR
Intervention: Brush protocol
Number of subjects: 25
Study 34462881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 28
Study 34462881 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreading Depolarization (SD) monitoring
Number of subjects: 28
Study 34462881 — intervention group
Group type: COMPARATOR
Intervention: Angiographic vasospasm
Number of subjects: 28
Study 34462881 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Cerebral Circulation Time (CCT)
Number of subjects: 28
Study 32246398 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) images
Number of subjects: 250
Study 32246398 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoramic Radiography (PR) images
Number of subjects: 250
Study 33461323 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (40 mg methylprednisolone)
Number of subjects: 44
Study 33461323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose (20% dextrose)
Number of subjects: 44
Study 34088588 — intervention group
Group type: EXPERIMENTAL
Intervention: Real (anodal) tDCS
Number of subjects: 24
Study 34088588 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 33057367 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systemic iron (lower sTFR and sTFR-ferritin index) and lower hsCRP levels in carriers of HFE variants
Number of subjects: 151
Study 33057367 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sTFR or iron stores, the HFE 187C>G variant, and lower baseline hsCRP
Number of subjects: 151
Study 36112487 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) based counseling sessions via telephone (up to three sessions)
Number of subjects: 497
Study 36112487 — intervention group
Group type: COMPARATOR
Intervention: Information brochure on responsible Internet use
Number of subjects: 497
Study 33852200 — intervention group
Group type: EXPERIMENTAL
Intervention: PRM 6 mg/day
Number of subjects: 0
Study 33852200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose PRM
Number of subjects: 0
Study 33852200 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose PRM
Number of subjects: 0
Study 33852200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33231635 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 916
Study 35758433 — intervention group
Group type: EXPERIMENTAL
Intervention: Central pancreatectomies
Number of subjects: 810
Study 35758433 — intervention group
Group type: EXPERIMENTAL
Intervention: No lymph nodes resected
Number of subjects: 810
Study 36309647 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM model
Number of subjects: 201
Study 36309647 — intervention group
Group type: EXPERIMENTAL
Intervention: LR model
Number of subjects: 201
Study 36309647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intermediate radiologist with LR radiomic model
Number of subjects: 201
Study 36309647 — intervention group
Group type: COMPARATOR
Intervention: Empirical diagnosis
Number of subjects: 201
Study 33813530 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management PEDSS intervention
Number of subjects: 283
Study 33813530 — intervention group
Group type: COMPARATOR
Intervention: Parent support and coping PEDSS intervention
Number of subjects: 283
Study 35721014 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous theta burst stimulation (cTBS) over the right cerebellar Crus I + 30-min speech-language therapy
Number of subjects: 40
Study 35721014 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous theta burst stimulation (cTBS)
Number of subjects: 40
Study 36339775 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 40 mg·kg‐1 + 10 mg·kg‐1·h‐1
Number of subjects: 40
Study 36339775 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil at an initial dose of 0.2 μg·kg‐1·min‐1
Number of subjects: 40
Study 32590148 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in blue space
Number of subjects: 59
Study 32590148 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in urban space
Number of subjects: 59
Study 32590148 — intervention group
Group type: COMPARATOR
Intervention: Resting at control site
Number of subjects: 59
Study 34819273 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg (subcutaneous) at week 0, week 4, then every 8 weeks through week 44
Number of subjects: 285
Study 34819273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossed over to guselkumab at week 24)
Number of subjects: 285
Study 34819273 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 285
Study 34819273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 32248626 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted counseling intervention with education and counseling by a physical therapist, use of a Fitbit and web application, and 4 follow-up calls from the physical therapist.
Number of subjects: 118
Study 32248626 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted counseling intervention
Number of subjects: 118
Study 36428216 — intervention group
Group type: EXPERIMENTAL
Intervention: IV melatonin at a daily dose of 60 mg, administered continuously for over 30 minutes starting on the day of diagnosis during a 5-day period.
Number of subjects: 29
Study 36428216 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 29
Study 35641993 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX-A) injection in the lateral pterygoid muscle
Number of subjects: 38
Study 35641993 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 38
Study 35352277 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 µg as a rapid intravenous bolus
Number of subjects: 70
Study 35352277 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 µg over 10 min infusion
Number of subjects: 70
Study 35352277 — intervention group
Group type: COMPARATOR
Intervention: Control group (prophylactic phenylephrine infusion)
Number of subjects: 70
Study 33226062 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Mendelian Randomization and Pleiotropy (IMRP) approach
Number of subjects: 0
Study 33226062 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32053567 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Integrated Neurocognitive Therapy (INT)
Number of subjects: 58
Study 32053567 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 58
Study 34184536 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific labeling of IgG antibodies using a two-step protocol with microbial transglutaminase.
Number of subjects: 0
Study 34184536 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-PAINT for labeling IgG antibodies.
Number of subjects: 0
Study 32932174 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg elemental zinc supplement
Number of subjects: 56
Study 32932174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 36171034 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer reviewers received a data sheet with trial registration information during the intervention phase.
Number of subjects: 419
Study 36171034 — intervention group
Group type: COMPARATOR
Intervention: Control phase with no changes to pre-existing peer review practices.
Number of subjects: 419
Study 36171034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase compared to control phase.
Number of subjects: 419
Study 36171034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention effect on primary outcomes.
Number of subjects: 419
Study 33345813 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronoidectomy
Number of subjects: 32
Study 33345813 — intervention group
Group type: COMPARATOR
Intervention: Coronoidotomy
Number of subjects: 32
Study 32800005 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls Management Exercise (FaME) programme
Number of subjects: 30
Study 32800005 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP)
Number of subjects: 30
Study 32800005 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 35508201 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Set Configuration (LSC: 4 sets of 10 repetitions with 2 min rest between sets)
Number of subjects: 24
Study 35508201 — intervention group
Group type: COMPARATOR
Intervention: Short Set Configuration (SSC: 8 sets of 5 repetitions with 51 s rest between sets)
Number of subjects: 24
Study 32879929 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinner group (spinning at 35 Ncm, n = 23)
Number of subjects: 50
Study 32879929 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable group (stable at 35 Ncm, n = 27)
Number of subjects: 50
Study 33064011 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 80
Study 33064011 — intervention group
Group type: COMPARATOR
Intervention: Microdebrider‐assisted inferior turbinoplasty (MAIT)
Number of subjects: 80
Study 33064011 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without anterior septal deviation
Number of subjects: 80
Study 33064011 — intervention group
Group type: COMPARATOR
Intervention: Patients with anterior septal deviation
Number of subjects: 80
Study 33596659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional educational intervention
Number of subjects: 38
Study 33596659 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 38
Study 32416145 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 75 mcg/day
Number of subjects: 65
Study 32416145 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 100 mcg/day
Number of subjects: 65
Study 32416145 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 200 mcg/day
Number of subjects: 65
Study 32416145 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day ring-free interval (substudy)
Number of subjects: 65
Study 32416145 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day ring-free interval (substudy)
Number of subjects: 65
Study 34991513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-based feeding (BCBO)
Number of subjects: 60
Study 34991513 — intervention group
Group type: COMPARATOR
Intervention: Standard care feedings
Number of subjects: 60
Study 33470769 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (tE2, n = 21)
Number of subjects: 72
Study 33470769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (n = 19)
Number of subjects: 72
Study 33470769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 72
Study 35508300 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point seed burying combined with fire dragon pot moxibustion
Number of subjects: 70
Study 35508300 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine nursing intervention of burying seeds at auricular points (Control)
Number of subjects: 70
Study 32546273 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive designs (ADs)
Number of subjects: 0
Study 32546273 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE abstract checklist
Number of subjects: 0
Study 34252286 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 date fruits/day for 4 weeks
Number of subjects: 48
Study 34252286 — intervention group
Group type: COMPARATOR
Intervention: Normal dietary intake without date fruit
Number of subjects: 48
Study 33051309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tech-supported model with video consultations
Number of subjects: 3533
Study 33051309 — intervention group
Group type: COMPARATOR
Intervention: Standard model with routine home visits by nurses and physicians
Number of subjects: 3533
Study 36081248 — intervention group
Group type: EXPERIMENTAL
Intervention: WBI + EMI
Number of subjects: 783
Study 36081248 — intervention group
Group type: COMPARATOR
Intervention: WBI-only
Number of subjects: 783
Study 36081248 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only
Number of subjects: 783
Study 36322258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (daily, weekly, or monthly)
Number of subjects: 0
Study 36322258 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cholecalciferol supplementation
Number of subjects: 0